Mettler-Toledo International (MTD) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 May, 2026Executive summary
Achieved 7% reported sales growth to $947.1 million in Q1 2026, with 3% local currency growth and 1% excluding acquisitions.
Adjusted EPS increased 9% to $8.91, supported by margin initiatives and innovation investments, while reported EPS was $8.33, up from $7.81.
Growth was led by strong industrial automation, food retailing, and bioprocessing segments, offset by softness in Western markets and chemical sectors.
Management remains confident in achieving solid adjusted EPS growth for the full year, with agility to navigate macroeconomic and geopolitical challenges.
Continued investment in innovation, automation, and digital tools positions the business for future growth.
Financial highlights
Net sales reached $947.1 million, up from $883.7 million in Q1 2025; gross profit was $555.8 million, with gross margin at 58.7%, down 80 bps year-over-year.
Adjusted operating profit was $246.2 million, up 4% year-over-year; adjusted operating margin at 26.0%, down 80 bps.
Net earnings for the quarter were $169.5 million, a 4% increase; diluted EPS was $8.33, up from $7.81.
Adjusted free cash flow was $119.7 million, impacted by higher tax payments; cash flow from operations was $139.8 million.
$206.3 million was spent on share repurchases in Q1 2026.
Outlook and guidance
Full-year 2026 local currency sales growth forecast at ~4%, with adjusted EPS guidance raised to $46.30–$46.95 (8–10% growth); FX expected to be a 2% sales benefit and neutral to EPS.
Q2 2026 local currency sales expected to grow ~3%, with adjusted EPS of $10.70–$10.85 (6–8% growth).
Free cash flow for 2026 expected at ~$900 million, up 5% per share; share repurchases of $825–$875 million planned.
Management expects sufficient liquidity for foreseeable needs, with ongoing monitoring of global trade, tariffs, and geopolitical risks.
Uncertainties from geopolitical conflicts and global tariffs may impact future results.
Latest events from Mettler-Toledo International
- Q2 2026 delivered robust sales and EPS growth, with guidance raised for the full year.MTD
Q2 202630 Jul 2026 - Q3 2025 delivered strong sales and EPS growth, with innovation and resilience amid tariff headwinds.MTD
Q3 20259 Jul 2026 - Q2 sales fell 4% but net earnings rose 4% and full-year EPS guidance was raised.MTD
Q2 20248 Jul 2026 - 2026 guidance targets 4% revenue growth, margin expansion, and full tariff mitigation.MTD
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q4 2025 delivered 8% sales and EPS growth, with a strong outlook for 2026.MTD
Q4 20258 Jul 2026 - Strong Q1 growth, tariff mitigation, and margin initiatives position the business for resilience.MTD
Bank of America 2025 Healthcare Conference8 Jul 2026 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance tempered by headwinds.MTD
Q4 20248 Jul 2026 - Q1 sales fell 5% to $883.7M, but margin gains and lab growth offset tariff headwinds.MTD
Q1 20258 Jul 2026 - Strong earnings, innovation, and China-led growth support a positive second-half outlook.MTD
Bank of America Global Healthcare Conference 202613 May 2026